Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Long-acting injection a shot in the arm for GSK’s HIV business

A long-acting injection developed by GlaxoSmithKline and given once a month proved as effective as standard daily pills for controlling the AIDS virus, lifting prospects for the British drugmaker’s key HIV business.

Read More »

Express Scripts staking out million dollar gene therapies

Express Scripts Holding Co. built a multi-billion enterprise pressuring drug companies to lower their prices for U.S. patients. Now the pharmacy benefit manager is quietly building a side business: getting paid to help drug companies dispense a new generation of high-priced drugs.

Read More »

New York sues OxyContin maker Purdue Pharma

New York state sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic.

Read More »

Getting too little sleep may ‘age’ the heart

Adults who sleep too little or too much may have an increased risk of heart attack or stroke, say researchers who argue that the best way to think of the harmful effect is in terms of “excess heart age.”

Read More »

Biogen’s muscle drug Spinraza too costly for Britain

Biogen’s muscle disease treatment Spinraza has been deemed too expensive for use on Britain’s state-run health service, even after a price discount offered by the U.S. drugmaker.

Read More »

‘Back-and-forth’ conversations with young kids may aid brain development

A new study suggests that how parents talk to children may matter just as much as how much time they spend talking.

Read More »

Amicus sets $315,000 price for new Fabry disease treatment

Amicus Therapeutics set an average price of $315,000 per year for the company’s newly approved Fabry disease treatment.

Read More »

Orchard raises $150 million to expand

Orchard Therapeutics raised a further $150 million to fund the biotech company’s work in gene therapy, building on earlier fundraisings worth more than $140 million.

Read More »

India’s Hetero pulls heart drug from U.S.

A unit of India’s Hetero Drugs is recalling some batches of the blood pressure and heart medicine valsartan in the United States amid a wider probe into cancer risks associated with the drug.

Read More »

Amicus receives U.S. approval for Fabry disease drug

U.S. health regulators approved Amicus Therapeutics’ Galafold as the first oral therapy to treat Fabry disease, a rare and sometimes fatal condition.

Read More »

Alnylam’s gene silencing drug wins FDA approval

Alnylam Pharmaceuticals’ Onpattro won U.S. regulatory approval for a rare hereditary disease, becoming the first approved treatment from a new class of medicines that use gene silencing technology.

Read More »

EU says second China company made tainted heart drug

The European Medicines Agency said a second Chinese contract manufacturer, Zhejiang Tianyu, produced a common blood pressure and heart drug with an impurity that could cause cancer.

Read More »

Obesity, diabetes in pregnancy may raise kids’ risk of psychiatric disorders

Pregnant women who have both severe obesity and diabetes may be more likely to have children with autism, ADHD and other psychiatric disorders than mothers who do not have either condition during pregnancy, a new study suggests.

Read More »

Experts weigh pros and cons of low-calorie sweetened drinks

Low-calorie sweetened beverages such as diet sodas that use aspartame or stevia may be a good replacement for full-sugar sodas and fruit juices, but researchers are still unsure about their long-term health effects, according to a new American Heart Association Science Advisory.

Read More »

Perrigo plans to separate prescription pharma business

Perrigo Co. Plc will separate the company’s generics prescription business – which has been a drag on results – to focus on consumer healthcare following a strategic review, sending the drugmaker’s shares down about 8 percent.

Read More »

U.S. joins lawsuits against Indivior, Reckitt over drug Suboxone

The U.S. Justice Department joined several whistleblower lawsuits against Indivior and Reckitt Benckiser Group, alleging that the drugmakers improperly marketed the opioid addiction treatment Suboxone.

Read More »

Nigeria approves $150 million World Bank loan to fight polio

Nigeria approved a $150 million loan from the World Bank to help eradicate polio and scale up immunization, Finance Minister Kemi Adeosun said.

Read More »

AstraZeneca settles Texas drug lawsuits

AstraZeneca agreed to settle two lawsuits brought by the state of Texas claiming that the drugmaker fraudulently marketed the antipsychotic drug Seroquel and Crestor for high cholesterol.

Read More »

Novo Nordisk Q2 2018 sales disappoint

Sales of some of Novo Nordisk’s key drugs in second-quarter 2018 fell short of expectations and the drugmaker said prices in the key U.S. market would be lower in 2019.

Read More »

Trump says will make announcement on reducing drug prices

U.S. President Donald Trump said his administration would make an announcement on reducing drug prices, but he did not offer specifics.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

June 2018 Focus: Biotech, Payer Access, DTC and more!


Ad Right Bottom

Main Navigation